SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals informs about press release

06 Sep 2016 Evaluate

Glenmark Pharmaceuticals has informed about a Press Release dated September 06, 2016 titled ‘Glenmark announces the Discovery and Initiation of IND-enabling studies of a novel Bispecific Monoclonal Antibody targeting EGFR’.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma Share Price

2227.40 -20.50 (-0.91%)
20-Apr-2026 14:22 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.90
Dr. Reddys Lab 1234.40
Cipla 1232.35
Zydus Lifesciences 936.50
Lupin 2328.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×